Alerts will be sent to your verified email
Verify Email
AMERISE
|
Amerise Biosciences
|
Clio Infotech
|
Wagend Infra Venture
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-0.9 % | -3.24 % | -12.28 % |
|
5yr average Equity Multiplier
|
1.27 | 1.61 | 1.1 |
|
5yr Average Asset Turnover Ratio
|
0.15 | 0.0 | 0.03 |
|
5yr Avg Net Profit Margin
|
1.22 % | -539.8 % | 1.75 % |
|
Price to Book
|
1.12 | 0.57 | 0.54 |
|
P/E
|
0.0 | 110.11 | 235.63 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 299.4 Days | 0.0 |
|
Inventory Days
|
0.0 | 230.25 Days | 217.6 Days |
|
Days Receivable
|
0.0 | 213.23 Days | 0.0 |
|
Days Payable
|
275.57 Days | 0.0 | 1134.91 Days |
|
5yr Average Interest Coverage Ratio
|
-475.34 | 20.05 | 0.0 |
|
5yr Avg ROCE
|
-0.92 % | 0.19 % | 0.74 % |
|
5yr Avg Operating Profit Margin
|
-0.04 % | -169.27 % | -28.73 % |
|
5 yr average Debt to Equity
|
0.01 | 0.48 | 0.0 |
|
5yr CAGR Net Profit
|
0.0 | n/a | n/a |
|
5yr Average Return on Assets
|
-1.74 % | -1.94 % | -11.24 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 0.0 | 0.0 |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -6.93 % | -7.49 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Amerise Biosciences
|
Clio Infotech
|
Wagend Infra Venture
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|